Altimmune to announce Q1 2025 financial results on May 13; conference call and webcast available for participants.
Quiver AI Summary
Altimmune, Inc., a late clinical-stage biopharmaceutical company, announced that it will release its first quarter 2025 financial results on May 13, 2025. A conference call to discuss these results and provide a business update will take place at 8:30 am E.T. on the same day and will be available via live webcast on the company's Investor Relations website. Participants can register to join the call and will have access to a recorded replay afterward. Altimmune specializes in developing next-generation peptide-based therapeutics, including pemvidutide, which targets obesity and related conditions. For further information, the company provides links to its website and social media.
Potential Positives
- Altimmune will provide a live conference call on May 13, allowing investors and analysts to gain insights into the company’s financial performance and business developments.
- The company is focused on innovative therapies, including pemvidutide, a dual receptor agonist with potential applications in several significant health issues, indicating strong R&D commitments.
- The pending financial results announcement may influence investor sentiment positively, as it provides an opportunity to communicate progress and future plans.
Potential Negatives
- Altimmune's status as a "late clinical-stage" biopharmaceutical company may imply a prolonged timeline to market, raising concerns about product viability and potential financial stability.
- The focus on multiple therapeutic areas, including obesity and alcohol-related conditions, could dilute the company's resources and attention, possibly affecting the development of their lead candidate.
- Future financial results, set to be reported, may reveal poor performance or unmet expectations, which can negatively affect investor confidence.
FAQ
When will Altimmune report its Q1 2025 financial results?
Altimmune will report its first quarter 2025 financial results on Tuesday, May 13, 2025.
What time is the Altimmune conference call?
The conference call is scheduled for 8:30 am E.T. on May 13, 2025.
How can I listen to the Altimmune conference call?
The conference call will be webcast live on Altimmune’s Investor Relations website.
What therapeutics is Altimmune developing?
Altimmune is developing pemvidutide, a dual receptor agonist for obesity and alcohol-related disorders.
Where can I find more information about Altimmune?
For more information, please visit Altimmune’s official website at www.altimmune.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALT Insider Trading Activity
$ALT insiders have traded $ALT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALT stock by insiders over the last 6 months:
- GREGORY L WEAVER (Chief Financial Officer) purchased 10,000 shares for an estimated $51,996
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALT Hedge Fund Activity
We have seen 93 institutional investors add shares of $ALT stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC added 1,378,854 shares (+35.6%) to their portfolio in Q4 2024, for an estimated $9,941,537
- CAPITAL FUND MANAGEMENT S.A. removed 726,829 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $5,240,437
- VANGUARD GROUP INC removed 552,246 shares (-11.1%) from their portfolio in Q4 2024, for an estimated $3,981,693
- UBS GROUP AG added 437,100 shares (+154.8%) to their portfolio in Q4 2024, for an estimated $3,151,491
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 426,043 shares (-46.0%) from their portfolio in Q4 2024, for an estimated $3,071,770
- GOLDMAN SACHS GROUP INC removed 406,655 shares (-43.6%) from their portfolio in Q4 2024, for an estimated $2,931,982
- MORGAN STANLEY removed 373,763 shares (-28.8%) from their portfolio in Q4 2024, for an estimated $2,694,831
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025.
Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors .
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com .
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]
Media Contact:
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
[email protected]
This press release was published by a CLEAR® Verified individual.
